Skip to main content

desmopressin acetate (Noqdirna®)

 

Following a full submission

AWMSG advice

Status: Recommended with restrictions

Desmopressin acetate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales. Desmopressin acetate (Noqdirna®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of nocturia due to idiopathic nocturnal polyuria in adults:

  • aged over 65, for whom treatment options are currently limited.

Desmopressin acetate (Noqdirna®) is not recommended for use within NHS Wales outside of this subpopulation.

 Final Recommendation: desmopressin acetate (Noqdirna) 3282 (PDF, 414Kb)
 Appraisal Report: desmopressin acetate (Noqdirna) 3282 (PDF, 298Kb)

Medicine details

Medicine name desmopressin acetate (Noqdirna®)
Formulation 25 micrograms, 50 micrograms sublingual tablet
Reference number 3282
Indication

Treatment of nocturia due to idiopathic nocturnal polyuria in adults

Company Ferring Pharmaceuticals (UK)
BNF chapter Endocrine system
Submission type Full
Status Recommended with restrictions
Advice number 1617
NMG meeting date 07/06/2017
AWMSG meeting date 13/09/2017
Date of issue 17/10/2017
Date of last review October 2020
Follow AWTTC: